Three genes — CALM1, CALM2 and CALM3 — are associated with heart function. A damaging variant in CALM1 causes calmodulinopathy.
Researchers from Boston Children’s Hospital said they have found a “safe and effective” pharmaceutical therapy for treating the disease, according to a Sept. 18 news release from the hospital. The antisense oligonucleotide pharmaceutical treatment targets the CALM1 gene variant at the RNA level without affecting the other CALM genes.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
